Sensus Healthcare prices $11m IPO

Sensus Healthcare (NSDQ:SRTSU) priced an $11 million initial public offering yesterday, saying it plans to float 2 million shares at $5.50 apiece starting today. Boca Raton, Fla.-based Sensus said the offering, expected to close June 8, also includes a 300,000-unit over-allotment option for the IPO’s underwriters. Each share consists of a unit of stock and a 3-year warrant with an exercise price of $6.75. The offering units are slated to split by July 25, with the stock shares trading on the NASDAQ exchange under the “SRTS” symbol and the warrants under the “SRTSW” symbol. Sensus makes low-energy photon X-ray systems for treating non-melanoma skin cancers, including basal cell and squamous cell carcinomas, and keloids. The company said March 9 that it planned to float more than 1.8 million shares at $10 to $12 apiece, working out to a low-end raise of $18.2 million and a high end of $21.8 million. Later that month, Sensus postponed the IPO. Last month, Sensus scaled back, saying it planned to offer 1.75 million shares at $6.25 apiece, for gross proceeds of $10.9 million. The SRT-100 system has U.S. 510(k) clearance, CE Mark approval in the European Union and approvals from the China Food &Drug Administration and Health Canada; Sensus claims more than 200 installed devices in 11 countries. The company had planned to put $3 million of the IPO proceeds toward hiring new sales reps and a director of marketing, a...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Funding Roundup Initial Public Offering (IPO) Radiosurgery Wall Street Beat Sensus Healthcare LLC Source Type: news

Related Links:

Re: Yang CJ, Kumar A, Gulack BC, Mulvihill MS, Hartwig MG, Wang X, et  al. Long-term outcomes after lobectomy for non–small cell lung cancer when unsuspected pN2 disease is found: A National Cancer Data Base analysis. J Thoracic Cardiovasc Surg. 2016;151:1380-8.
Source: The Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Tags: Notice of Correction Source Type: research
Analyst, 2019, Advance Article DOI: 10.1039/C9AN00691E, PaperBo Yin, Sha Sha Li, Shao Hua Lu, Jia Ying Mi, Hong Lin Zhai The feature information was extracted from the 3D spectrum by the TM method, and the simultaneous quantification of intracellular thiols was realized. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Analyst latest articles - Category: Chemistry Authors: Source Type: research
AbstractA novel series of coumarin-pyridine/fused pyridine hybrids were designed and synthesized. Their anticancer activity was evaluated against human cancer cell lines MCF-7, HCT-116, HepG-2, and A549. Compounds9,10, and11 showed the most potent growth inhibitory activities with IC50 values ranging from 1.1 to 2.4  μM, against MCF-7 cell line. Flow cytometric analysis revealed that these compounds induced cell cycle arrest in the G2/M phase followed by apoptotic cell death. Consistent with these results, the activity of caspase-3 in MCF-7 cells was tested. The results indicated that compounds9,10, and11 increas...
Source: Medicinal Chemistry Research - Category: Chemistry Source Type: research
(Medical College of Georgia at Augusta University) A checkpoint may delay travelers but it can help give cancer free rein by suppressing the natural immune response that should destroy it, researchers say.
Source: EurekAlert! - Biology - Category: Biology Source Type: news
Contributors : Rui Kuang ; Wei ZhangSeries Type : OtherOrganism : Homo sapiensThe NanoString experiment were conducted on 59 cell lines including 12 ovary cell lines, 12 lung cell lines, 11 colon cell lines, 10 breast cell lines, 4 pancreas cell lines, 2 prostate cell lines, 2 stomach cell lines, and 6 cell lines of 6 other types of tissues. A total of 403 probes were customized to estimate the isoform expressions of 155 cancer genes curated from the literature with more reliable isoform annotations, where each of the 155 gene contains at least two isoforms.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Other Homo sapiens Source Type: research
Contributors : Shin-ichiro Ohno ; Masahiko KurodaSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensIn order to identify divergent transcripts involved in cancer development, next-generation sequencing analysis of RNA extracted from cancer and normal lung tissue was performed.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
ConclusionsManagement of patients with advanced rectal cancer and radiologically positive lateral pelvic lymph nodes is challenging due to high local recurrence rates. Further studies are needed to develop care pathways for the optimal treatment processes.
Source: Journal of Gastrointestinal Surgery - Category: Surgery Source Type: research
Superficial radiation therapy device developer Sensus Healthcare (NSDQ:SRTSU) today released plans for a global expansion, including new distribution agreements in China, Germany, Mexico, Cuba and Costa Rica. Sensus makes low-energy photon X-ray systems for treating non-melanoma skin cancers, including basal cell and squamous cell carcinomas, and keloids. The Boca Raton, Fla.-based company refers to the technology as superficial radiation therapy, and claims that the tech has been sued to “effectively and safely treat oncological and non-oncological skin conditions.” “Following our new partnersh...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Distribution Oncology Sensus Healthcare LLC Source Type: news
Sensus Healthcare is a medical device company that focuses on providing non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids utilizing superficial radiation technology (SRT). Their proprietary, FDA-cleared SRT technology...
Source: Medgadget - Category: Medical Devices Authors: Tags: Dermatology Exclusive Oncology Source Type: blogs
Sensus Healthcare (NSDQ:SRTSU) said today it closed its initial public offering, raising $11 million through the sale of 2.3 million units at $5.50 each. The offering included a fully-exercised underwriters option of an additional 300,000 units at the IPO price, Sensus said. Each share consists of a unit of stock and a 3-year warrant with an exercise price of $6.75. The offering units are slated to split by July 25, with the stock shares trading on the NASDAQ exchange under the “SRTS” symbol and the warrants under the “SRTSW” symbol. Sensus makes low-energy photon X-ray systems for treating non...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Funding Roundup Initial Public Offering (IPO) Radiosurgery Sensus Healthcare LLC Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Funding | Health | Keloids | Marketing | Medical Devices | Melanoma | Nonmelanoma Skin Cancer | Skin | Skin Cancer | Sports Medicine | Squamous Cell Carcinoma